GENinCode Plc (AIM:GENI)

Market Cap	7.17M
Revenue (ttm)	2.60M
Net Income (ttm)	-5.94M
Shares Out	286.88M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,017
Average Volume	528,120
Open	2.569
Previous Close	2.500
Day's Range	2.568 - 2.569
52-Week Range	2.200 - 9.760
Beta	0.81
RSI	37.02
Earnings Date	Jun 12, 2025

About GENinCode

GENinCode Plc develops and commercializes clinical genetic tests to provide predictive analysis of risk to a patient’s health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company’s molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular pr...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2018
• Employees: 42
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: GENI

Financial Performance

In 2023, GENinCode's revenue was 2.16 million, an increase of 51.05% compared to the previous year's 1.43 million. Losses were -7.02 million, 26.2% more than in 2022.